Welcome
Cardiorentis is a privately owned biopharmaceutical company designed for the new world of drug development
Acute heart failure
AHF can be defined as the sudden or gradual onset of the signs or symptoms of heart failure resulting in a need for urgent therapy or hospitalisation.
Ularitide
Ularitide is an advanced natriuretic peptide in Phase III development as an intravenous (IV) infusion treatment for acute heart failure (AHF).
Welcome to Cardiorentis AG
Cardiorentis AG is a privately owned pharmaceutical company based in Zug, Switzerland.
Focused, fast moving, flexible, with patients at its heart, Cardiorentis
is committed to introducing the first therapy with proven outcome
benefits for patients with acute heart failure and developing innovative
medicines for diseases of high unmet medical need.
Latest News
-
10-01-2016
Press release
Cardiorentis Raises CHF 60 Million in Series B Financing and Adds Two Key Senior Executives
-
11-12-2015
Press release
Cardiorentis’ Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure: